Abstract
The increasing knowledge of the genetics and molecular biology of human disease, particularly in human cancer (Culver and Blaese 1994), has led to the application of new biological approaches in therapy. A limitation of many biological-based therapies has been our inability to achieve controlled and effective delivery of biologically active molecules to tumor cells or their surrounding matrix. This condition is particularly limiting for biologically active compounds that have very short half-lives and exhibit site-specific therapeutic and toxic effects. Gene-based therapy can provide control over the level, timing, and duration of action of these biologically active products by including specific promoter/activator elements in the genetic material transferred, resulting in more effective therapeutic interventions. Methods are actively being developed for controlled gene delivery to various somatic tissues and tumors using novel formulations of DNA and for controlling gene expression using cell-specific, replication-activated, and drug-controlled expression systems (Jolly 1994).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alauddin MM, Conti PS, Lever JR, Mazza SM, Hamzeh FM (1996) Synthe-sisof F-18 9-[(3-fluoro-1-hydroxy-2-propoxy)-methyl]-guanine (FHPG) for in vivo imaging of viral infection and gene therapy with PET. J Nuel Med 37:5, 193P
Blasberg RG, Roelcke U, Weinreich R, von Ammon. K, Crompton N, Guenther I, Knust E, Beattie B, Finn R, Leenders K (1996) [124I]-Iododeoxyuridine imaging tumor proliferation. J Nucl Med 37:5, 54P
Blasberg RG, Groothuis D, Molnar P (1981) Application ofquantitative autoradiographic measurements in experimental brain tumormodels. Semin Neurol 1:203–223
Blasberg RG, Gazendam J, Patlak CS, Fenstermacher JD (1980) Quantitative autoradiographic studies of brain edema and acomparison of multi-isotope autoradiographic techniques. In: Cervos-Navarosand J, Ferszt S (eds) Brain edema. Raven, New York, pp 255–270 (Advances in neurology, vol 28)
Blum MR, Liao SH, deMiranda P (1982) Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med 73:197–201
Borrelli E, Heyman R, Hsi M, Evans RM (1988) Targetingof an inducible toxic phenotype in animal cells. Proc Natl Acad SciUSA 85:7572–7576
Clinical Protocol List (1995) Cancer Gene Ther 2 (3):225
Culver KW, Blaese RM (1994) Gene therapy for cancer. Trends in Genet 10:174–178
Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producercells for treatment of experimental brain tumors. Science 256:1550–1552
Feinberg A, Leyland-Jones B, Fanucchi MP, Hancock C, Fox JJ, Watanabe KA, Vidal PM, Williams L, Young CW, Philips FS (1985) Biotransformation and elimination of 2-[14C]-5-iodo-(2′-fluoro-2′-deoxy-1-β-D-arabino-furanosyl)-cytosine in immunosuppressed patients with herpesvirus infections. Antimicrob Agents Chemother 27(5):733–738
Fletcher C, Sawchuk R, Chinnock B, deMiranda P, Balfour HH Jr (1986) Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 40:281–286
Ghattas IR, Sanes JR, Majors JE (1991) The encephalomyocarditisvirus internal ri-bosome entry site allows effieicnt coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 11:5848
Haberkorn U, Altmann A, Morr I, Germann C, van Kaick G. (1996) Uptake of specific substrates for HSV thymidine kinase in genetically modifiedhepa-toma cells. J Nucl Med 37:5, 235P
Haberkorn U, Oberdorfer F, Gebert J, Morr I, Haack K, Weber K, Lindauer M, van Kaick G, Schackert HK (1996) Monitoring gene therapy with cytosine deaminase: in vitro studies using tritated-5-fluoroeytosine. J Nucl Med 37: 87–94
Iwashina T, Tovell DR, Xu L, Tyrrell DL, Knaus EE, Wiebe LI (1988) Synthesis and antiviral activity of IVFRU, a potential probe for the non-invasive diagnosis of herpes simplex encephalitis. Drug Design Deliv 3:309–321
Jolly D (1994) Viral vector systems for gene delivery. Cancer Gene Therapy 1(1):51–64
Ko L, Koestner A, Wechsler W (1980) Morphological characterisation of nitro-surea-induced glioma cell lines and clones. Acta Neuropathol (Berl) 84:529–541
Kong XB, Vidal P, Tong WP, Chiang J, Gloff CA, Chou TC (1992) Preclinical pharmacology of the anti-hepatitis virus agent 2′fluoro-5-ethyl-lbeta-D-arabinofuranosyluracil in mice and rats. Antimierob Agents Chemother 36:1472–1477
Manthorpe M, Cornefert-Jensen F, Hartikka J, Felgner J, Rundell A, Margalith M, Dwarki V (1993) Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Human Gene Ther 4(4):419–431
McKenzie R, Fried MW, Sallie R et al (1995) Hepatic failureand lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333:1099–1105
Misra HK, Knaus EE, Wiebe LI, Tyrell DL (1986) Synthesis of 131I, 125I, 123I and Br labelled 5-halo-1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) uracils. Appl Radiat Isot 37:901–905
Molnar P, Groothuis D, Blasberg R, Zaharko D, Owens E, Fenstermacher J (1984) Regional thymidine transport and incorporation in experimental brain and subcutaneous tumorsJ Neurochem 43(2):421–432
Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase gene: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276–5281
Moolten FL, Wells JM (1990) Curability of tumors bearing herpes thymidine kinase genes transfected by retroviral vectors. J Natl Cancer Inst 82(4):297–300
Mullen CA, Kilstrup M, Blase M (1992) Transfer of the bacterial gene for cy-tosine deaminase to mammalian cells confers lethal sensitivity to 5-fluoro-cytosine: a negative selection system. Proc Natl Acad Sci USA 89:33–37
Mulligen R, Berg P (1981) Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyl transferase. Proc Natl Acad Sci USA 78:2072–2076
Price J, Turner D, Cepko C (1987) Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 84:156–160
Price R, Cardle K, Watanabe K (1983) The use of antiviral drugs to image herpes encephalitis. Cancer Res 43: 3619–3627
Saito Y, Price RW, Rottenberg DA, Fox JJ, Su T-L, Watanabe KA, Philips FA (1982) Quantitative autoradiographic mappingof herpes simplex virus encephalitis with radiolabeled antiviral drug. Science 217:1151–1153
Saito Y, Rubenstein R, Price RW, Fox JJ, Watanabe KA (1984) Diagnostic imaging of herpes simplex virus encephalitis using radiolabeled antiviral drug: autoradiographic assessment in animal model. Ann Neurol 15:548–558
Sokolic RA, Sekhsaria S, Sugimoto Y, Whiting-Theobald N, Linton GF, Li F, Gottesman MM, Malech HL (1996) A bicistronic retrovirus vector containing a Picornavirus internal ribosome entry site allows for correction of X-Linked CGD by selection for MDR1 expression. Blood 87(1):42–50
Srinivasan A, Gambhir SS, Green AL et al (1996) A PET reporter gene (PRG)/PET reporter probe (PRP) technology for repeatedly imaging gene expression in living animals. J Nucl Med 37:5, 107P
Sugimoto Y, Aksentijevich I, Murray GJ, Brady RO, Pastan I, Gottesman MM (1995a) Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. Human Gene Ther 6:905–915
Sugimoto Y, Hrycyna CA, Aksentijevich I, Pastan I, Gottesman MM (1995b) Coexpression of a multidrug-resistance gene (MDR1) and herpes simplex virus thymidine kinase gene as part of a bicistronic messenger RNA in a retrovirus vector allows selective killing of MDR1-transduced cells.Clin Can Res 1:447–457
Tjuvajev JG, Muraki A, Ginos J, Berk J, Koutcher J, Ballon D, Beattie B, Finn R, Blasberg R (1993) Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med 34:1152–1162
Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, Kothari P, Desai R, Zhang Z, Beattie B, Graham M, Larson S, Blasberg RG (1994) Imaging of brain tumor proliferativeactivity with iodine-131-iodode-oxyuridine. J Nucl Med 35:1407–1417
Tjuvajev J, Stockhammer G, Desai R, Uehara H, Watanabe K, Gansbacher B, Blasberg R (1995) Imaging the expression of transfected genes in vivo. Cancer Res 55:6126–6132
Tjuvajev JG, Finn R, Watanabe K, Joshi R, Oku T, Kennedy J, Beattie B, Koutcher J, Larson S, Blasberg RG (1996) Noninvasive imaging of herpesvirus thymidine kinase gene transfer and expression: a potential methodfor monitoring clinical gene therapy. Cancer Res 56:4087–4095
Tovell D, Yacyshyn H, Misra H, Knaus EE, Wiebe LI, Samuel J, Gill MJ, Tyrrell LJ (1987) Effect of acyclovir on the uptake of 131I-labeled 5-iodo-(2′-fluoro-2′-deoxy-1-α-D-arabino-furanosyl)-uracil in herpes infected cells. J Med Virol 22:183–188
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Blasberg, R.G., Tjuvajev, J.G. (1997). In Vivo Monitoring of Gene Therapy by Radiotracer Imaging. In: Semmler, W., Schwaiger, M. (eds) Impact of Molecular Biology and New Technical Developments in Diagnostic Imaging. Ernst Schering Research Foundation Workshop, vol 22. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60844-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-60844-5_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64581-5
Online ISBN: 978-3-642-60844-5
eBook Packages: Springer Book Archive